Beranda › Skleroderma › Pennsylvania › Pittsburgh
Uji klinis Skleroderma di Pittsburgh, PA
5 studi untuk Skleroderma mencari peserta di lokasi sekitar Pittsburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Menerima pesertaFase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Menerima pesertaFase 2/3
- GSK Investigational Site, Pittsburgh
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
Menerima pesertaFase 2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
Intralesional Injection of STS in Treatment of Calcinosis
Menerima pesertaFase 2
- UPMC Arthritis and Autoimmunity Center, Pittsburgh
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
Menerima peserta
- University of Pittsburgh and UPMC Scleroderma Center, Pittsburgh
Uji klinis Skleroderma di kota lain
- New York City, NY11 studi
- Chicago, IL10 studi
- Ann Arbor, MI10 studi
- Houston, TX9 studi
- Durham, NC7 studi
- Los Angeles, CA7 studi
- Boston, MA7 studi
- Baltimore, MD6 studi
- New Orleans, LA6 studi
- Philadelphia, PA6 studi
- Dallas, TX5 studi
- Phoenix, AZ4 studi
Studi lain di Pittsburgh
- Kanker Paru Non-Sel Kecil48 studi
- Kanker (semua jenis)41 studi
- Kanker Payudara39 studi
- Kanker Kolorektal32 studi
- Melanoma31 studi
- Kanker Metastatik31 studi
- Kanker Ovarium30 studi
- Kanker Prostat23 studi
- Kanker Paru23 studi
- Kanker Endometrium23 studi
- Stroke22 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.